Filing Details
- Accession Number:
- 0001209191-21-031300
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-05-10 13:00:00
- Reporting Period:
- 2021-05-07
- Accepted Time:
- 2021-05-10 17:06:48
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1699382 | Pmv Pharmaceuticals Inc. | PMVP | Pharmaceutical Preparations (2834) | 463218129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1825216 | Leila Alland | C/O Pmv Pharmaceuticals, Inc. 8 Clarke Drive, Suite 3 Cranbury NJ 08512 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-05-07 | 4,000 | $3.90 | 4,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-05-07 | 3,842 | $34.80 | 158 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-05-07 | 158 | $35.49 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Disposition | 2021-05-07 | 4,000 | $0.00 | 4,000 | $3.90 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
369,850 | 2030-02-04 | No | 4 | M | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.30 to $35.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.47 to $35.50, inclusive.
- One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter.